Filing Flows › Comparisons › KRYS vs IOVA
Krystal Biotech vs Iovance Biotherapeutics: KRYS and IOVA compared
Krystal Biotech is the larger company: $127M of revenue in its latest quarter (Q3 2026) against $121M for Iovance Biotherapeutics (Q3 2026). Iovance Biotherapeutics is growing faster (+80% against +30% a year earlier). Krystal Biotech is more profitable, with an operating margin of 55.9% against -19.7%.
Where the money goes: KRYS and IOVA
Krystal Biotech (KRYS) · Q3 2026
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
Iovance Biotherapeutics (IOVA) · Q3 2026
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Krystal Biotech (KRYS) | Iovance Biotherapeutics (IOVA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $127M | $121M |
| Revenue growth, Y/Y | +30% | +80% |
| Operating margin | 55.9% | -19.7% |
| Net earnings | $63.1M | −$22.3M |
| Net margin | 49.5% | -18.3% |
| Operating cash flow | $91.2M | −$4.5M |
| Free cash flow | $90.3M | — |
| Market value | — | $6.6B |
| Analysts’ mean target | — | $14.50 |
Questions
Which is bigger, Krystal Biotech or Iovance Biotherapeutics?
Krystal Biotech is the larger company: $127M of revenue in its latest quarter (Q3 2026) against $121M for Iovance Biotherapeutics (Q3 2026).
Is Krystal Biotech or Iovance Biotherapeutics growing faster?
Iovance Biotherapeutics is growing faster (+80% against +30% a year earlier).
Which is more profitable, Krystal Biotech or Iovance Biotherapeutics?
Krystal Biotech is more profitable, with an operating margin of 55.9% against -19.7%.
More: Krystal Biotech earnings · how Krystal Biotech makes money · Iovance Biotherapeutics earnings · how Iovance Biotherapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.